Naca

Phase 2

AArctic Therapeutics

Naca is one of 5 therapeutic programs targeting Amyloid. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AmyloidActive, not recruiting

AmyloidPhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Amyloid

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Approved

1 2

Tecvayli

Johnson & Johnson

Phase 2

1 3

DARZALEX FASPRO

Johnson & Johnson

Phase 2

1 4

Amyvid

IInvicro

Phase 2

2 5

Naca

AArctic Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Amyloid

NCT07716865

Clinical

Trials by Indication[1]

Amyloid1 trial

Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

Active, not recruiting·AArctic Therapeutics·Phase 2·NCT07716865·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Naca. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Naca. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Arctic Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AArctic Therapeutics

Naca

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Amyloid1 trial

References

Drug Info

Quick Facts

Related News